| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | WZ3105 | GDSC1000 | pan-cancer | AAC | 0.04 | 0.2 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | -0.046 | 0.2 |
| mRNA | BRD-K64610608 | CTRPv2 | pan-cancer | AAC | -0.051 | 0.2 |
| mRNA | navitoclax:piperlongumine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.047 | 0.2 |
| mRNA | COL-3 | CTRPv2 | pan-cancer | AAC | -0.049 | 0.2 |
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | -0.1 | 0.2 |
| mRNA | KIN001-135 | GDSC1000 | pan-cancer | AAC | 0.071 | 0.2 |
| mRNA | MS-275 | gCSI | pan-cancer | AAC | -0.068 | 0.2 |
| mRNA | TGX221 | CTRPv2 | pan-cancer | AAC | 0.048 | 0.2 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | -0.047 | 0.2 |